Jesse Fishman, PharmD, MSc

Director, HEOR
Apellis Pharmaceuticals, Inc., Waltham, MA, USA

Poster(s):

• (150) Comparative Effectiveness of Pegcetacoplan (PEG) Versus Ravulizumab (RAV) and Eculizumab (ECU) in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Matching-Adjusted Indirect Comparison
  Saturday, August 26, 2023

  8:00 AM – 6:00 PM ADT

• (158) Healthcare Resource Utilization from OPERA: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria
  Sunday, August 27, 2023

  8:00 AM – 1:30 PM ADT